摘要
[目的]系统评价国内有关乳腺癌组织中Ki67表达及其临床意义的病例对照研究。[方法]计算机检索CBM、CNKI、VIP和万方数据库，并辅以文献追溯的方法，收集国内公开发表的所有关于乳腺癌组织中Ki67表达及其与临床病理特征关系的病例对照研究。检索年限均从建库至2013年10月1013。按纳入和排除标准筛选文献并评价纳入研究质量后，应用RevMan5．0和Statal2．0软件进行Meta分析。[结果]共纳入12个病例对照研究，其中乳腺癌756例，非乳腺癌1421例。Meta分析结果显示，Ki67在乳腺癌组与非乳腺癌组（OR=6．01，95％CI：4．72-7．66）、乳腺癌临床Ⅰ-Ⅱ期组与Ⅲ-Ⅳ期组（OR=0．33，95％CI：0．18—0．61）、乳腺癌患者年龄≤35岁组与〉35岁组（OR=1．91，95％CI：1.37-2．66）的表达差异均有统计学意义；Ki67在乳腺癌有淋巴结转移组与无淋巴结转移组（OR=1．53,95％CI：0．98～2．39）表达差异则无统计学意义。[结论]Ki67可能在乳腺癌中过度表达，其表达与乳腺癌的临床病理特征密切相关，对乳腺癌的早期诊断、治疗及预后判断具有重要意义．但其能否作为乳腺癌诊断及预后的可靠指标尚不确定，需要进行更多设计严谨、细致的高质量流行病学研究来进一步证实。
[ Purpose ] To investigate the case-control studies addressing the expression and clini- cal significance of Ki67 in human breast cancer with meta-analysis. [Methods] A computer- based retrieval of CBM,VIP,CNKI and Wanfang Database was performed from their establish- ment to October 2013 for case-control studies investigating the Ki67 expression and clinical significance in breast cancer. The quality of the included studies was assessed. The data were analyzed by RevMan5.0 and Statal2.0 softwares. [Results] A total of 12 studies were recruited. As for the positive rate of Ki67,significant differences were tested between breast cancer group vs normal breast tissues group, breast cancer clinical stages Ⅰ -Ⅱ group vs Ⅲ- Ⅳ group, breast cancer ≤35 years old group vs 〉35 years old group with OR（95%CI） at 6.01 （4.72-7.66）,0.33 （0.18-0.61） and 1.91 （1.37-2.66）,respectively. No significant difference was tested between lymph node metastasis group vs non-lymph node metastasis group with OR （95%CI） at 1.53 （0.98-2.39）. [Conclusion] According to the domestic evidence,Ki67 may be participated the whole course of carcinogenesis of breast cancer, which might be valuable for the early diagno- sis, treatment and prognosis, but is not the absolute factor for estimating the survival rate of the patients with breast cancer, and more high-quality studies are expected for further study.
出处
《肿瘤学杂志》
CAS
2014年第4期270-275,共6页
Journal of Chinese Oncology
